Dr. Pal Discusses the Role of PD-L1 in Metastatic RCC

Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma (RCC). One of the biggest unanswered questions in the frontline setting of metastatic RCC is the role of PD-L1. Pal says that there is more to the PD-L1 story, particularly considering the findings of the CheckMate-214 trial. There was a clear difference in clinical outcomes for patients who were PD-L1– positive versus PD-L1–negative, Pal explains. Whether that is clinically applicable is not established.06/28/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news